Product Information
ZORYVE 0.3% FOAM is a brand product labeled by Arcutis Biotherapeutics, Inc., priced at $15.3795 per GM under NDC 80610043060. Its NADAC has been published 115 times since Apr 17, 2024.
The High Outlier badge above means this manufacturer's average price in the roflumilast market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3 mg/g
Manufacturer
Arcutis Biotherapeutics, Inc.NDC
80610043060
Classification
Brand
Dosage Form
AEROSOL, FOAM
Route
TOPICAL
Last Updated
6/17/2026
Active Ingredients
ROFLUMILASTApproval Type
New Drug (NDA)
FDA Application
NDA217242On Market Since
12/15/2023
Pharmacological Classes
Price Statistics
The NADAC for ZORYVE 0.3% FOAM has been published 115 times since Apr 17, 2024, and over the history we have for it it has risen 12.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.3795 per GM |
|---|---|
| All-time high | $15.3897 (May 13, 2026) |
| All-time low | $13.6685 (Jun 19, 2024) |
| 52-week high | $15.3897 |
| 52-week low | $14.7978 |
| Median price | $14.7945 |
| Average price | $14.6837 |
| Largest weekly change | +4.0% (Jan 7, 2026) |
| Weeks tracked | 115 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ZORYVE 0.3% FOAM?
The current National Average Drug Acquisition Cost (NADAC) for ZORYVE 0.3% FOAM, manufactured by Arcutis Biotherapeutics, Inc., is $15.3795 per GM (NDC 80610043060), effective Jun 24, 2026.
How has the price of ZORYVE 0.3% FOAM changed over time?
Over the history we have for it, the NADAC for ZORYVE 0.3% FOAM has risen 12.1%. It has been tracked across 115 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ZORYVE 0.3% FOAM?
Since Apr 17, 2024, the NADAC for ZORYVE 0.3% FOAM has ranged from a low of $13.6685 (Jun 19, 2024) to a high of $15.3897 (May 13, 2026), with a median of $14.7945 per GM.
Are there cheaper alternatives to ZORYVE 0.3% FOAM?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, ZORYVE 0.3% CREAM, is $15.3781 per GM — about 0% below ZORYVE 0.3% FOAM.
Who manufactures ZORYVE 0.3% FOAM?
ZORYVE 0.3% FOAM (NDC 80610043060) is labeled by Arcutis Biotherapeutics, Inc., and CMS classifies it as a brand product.